IPO registrations (S-1, F-1) · Registrants
Marker Therapeutics, Inc.
- SEC CIK
- 1094038 · filings on EDGAR ↗
- Former names
- TAPIMMUNE INC. (2017–2018); TAPIMMUNE INC (2007–2017); GENEMAX CORP (2002–2007); EDUVERSE COM (1999–2002)
- Registration
- Form S-1, first filed 2010-06-16, last 2022-12-23; 3 initial registrations, 2 amendments
- Outcome
- Declared effective 2010-08-05; withdrawal requested 2011-06-01
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 2450 HOLCOMBE BLVD, TMC PARTNERS OFFICE 1.311, Houston, TX 77021
- EIN
- 88-0277072
- Ticker
- MRKR (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Marker Therapeutics, Inc. on the corporate pages
On this site
- Business registration: MARKER THERAPEUTICS, INC. Fuzzy (name and state)
- Business registration: MARKER THERAPEUTICS, INC. Fuzzy (name and state)
- Federal award recipient: MARKER THERAPEUTICS INC Fuzzy (name and state)
- Form D issuer: Marker Therapeutics, Inc. EXACT (CIK (EXACT))
- SEC filer: Marker Therapeutics, Inc. EXACT (CIK (EXACT))
Filings 18
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2010-06-16 | S-1 | S-1 (registration) | TAPIMMUNE INC | 0001424884-10-000074 ↗ |
| 2010-08-02 | S-1/A | S-1/A (amendment) | TAPIMMUNE INC | 0001424884-10-000103 ↗ |
| 2010-08-04 | S-1/A | S-1/A (amendment) | TAPIMMUNE INC | 0001424884-10-000107 ↗ |
| 2010-08-05 | EFFECT | EFFECT (declared effective) | TAPIMMUNE INC | 9999999995-10-002369 ↗ |
| 2011-06-01 | RW | RW (withdrawal request) | TAPIMMUNE INC | 0001424884-11-000090 ↗ |
| 2014-07-23 | EFFECT | EFFECT (declared effective) | TAPIMMUNE INC | 9999999995-14-002196 ↗ |
| 2015-07-16 | EFFECT | EFFECT (declared effective) | TAPIMMUNE INC | 9999999995-15-001940 ↗ |
| 2015-07-20 | S-1 | S-1 (registration) | TAPIMMUNE INC | 0001424884-15-000100 ↗ |
| 2015-08-07 | EFFECT | EFFECT (declared effective) | TAPIMMUNE INC | 9999999995-15-002218 ↗ |
| 2016-06-10 | EFFECT | EFFECT (declared effective) | TAPIMMUNE INC | 9999999995-16-004877 ↗ |
| 2017-01-18 | EFFECT | EFFECT (declared effective) | TAPIMMUNE INC | 9999999995-17-000144 ↗ |
| 2017-12-29 | EFFECT | EFFECT (declared effective) | TAPIMMUNE INC. | 9999999995-18-000012 ↗ |
| 2018-11-16 | EFFECT | EFFECT (declared effective) | Marker Therapeutics, Inc. | 9999999995-18-002918 ↗ |
| 2019-06-25 | EFFECT | EFFECT (declared effective) | Marker Therapeutics, Inc. | 9999999995-19-001442 ↗ |
| 2021-08-19 | EFFECT | EFFECT (declared effective) | Marker Therapeutics, Inc. | 9999999995-21-003254 ↗ |
| 2022-12-23 | S-1 | S-1 (registration) | Marker Therapeutics, Inc. | 0001104659-22-129742 ↗ |
| 2022-12-30 | EFFECT | EFFECT (declared effective) | Marker Therapeutics, Inc. | 9999999995-23-000015 ↗ |
| 2024-12-06 | EFFECT | EFFECT (declared effective) | Marker Therapeutics, Inc. | 9999999995-24-003698 ↗ |
Prospectus pages read 1
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2022-12-23 | S-1 | registration statement | $4.27 | - | - | Nasdaq MRKR | 0 | primary document; price line | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| CORIN DENIS | Director,Officer; Officer | President; President and CEO; President and CFO | 7 | 2007–2012 | |
| LINDSAY ALAN P | Director | 2 | 2007–2009 | ||
| MCGOWAN PATRICK A | Director,Officer | Secretary, Treasurer & CFO | 1 | 2007 | |
| WILSON GLYNN | Director; Director,Officer | CEO; Chairman and CEO; Chief Executive Officer; Executive Chairman | 10 | 2007–2018 | |
| Jefferies Wilfred Arthur | TenPercentOwner | 1 | 2007 | ||
| MOORE TRACY A | Director,Officer | Chief Financial Officer | 2 | 2009 | |
| DePippo Lynn | Director | 1 | 2011 | ||
| Reddish Mark | Director; Officer | Vice President | 5 | 2012–2018 | |
| DART KENNETH BRYAN | TenPercentOwner | 9 | 2015–2020 | ||
| Eastern Capital LTD | TenPercentOwner | 9 | 2015–2020 | ||
| Portfolio Services Ltd. | TenPercentOwner | 9 | 2015–2020 | ||
| BONFIGLIO JOHN N | Director; Director,Officer | President and COO; See Remarks | 5 | 2015–2017 | |
| Grisewood Sherry | Director | 5 | 2015–2018 | ||
| Laskow-Pooley David | Director | 8 | 2015–2022 | ||
| Wasserman Frederick Gerald | Director | 8 | 2016–2021 | ||
| Loiacono Michael | Officer | Chief Accounting Officer; Chief Financial Officer | 7 | 2016–2023 | |
| Silverman Joshua | Director | 5 | 2016–2018 | ||
| Hoang Peter L. | Director,Officer | CEO and President; Chief Executive Officer; President and CEO | 9 | 2017–2022 | |
| BARRIS PETER J | TenPercentOwner | 1 | 2018 | ||
| BASKETT FOREST | TenPercentOwner | 3 | 2018–2024 | ||
| Behbahani Ali | Director; TenPercentOwner | 3 | 2018–2024 | ||
| Chang Carmen | TenPercentOwner | 3 | 2018–2024 | ||
| Florence Anthony A. Jr. | TenPercentOwner | 3 | 2018–2024 | ||
| Makhzoumi Mohamad | TenPercentOwner | 3 | 2018–2024 | ||
| MAKOWER JOSHUA | TenPercentOwner | 2 | 2018–2021 | ||
| MOTT DAVID M | TenPercentOwner | 1 | 2018 | ||
| NEA 16 GP, LLC | TenPercentOwner | 3 | 2018–2024 | ||
| NEA Partners 16, L.P. | TenPercentOwner | 3 | 2018–2024 | ||
| New Enterprise Associates 16, L.P. | TenPercentOwner | 3 | 2018–2024 | ||
| SANDELL SCOTT D | TenPercentOwner | 3 | 2018–2024 | ||
| Sonsini Peter W. | TenPercentOwner | 2 | 2018–2021 | ||
| Viswanathan Ravi | TenPercentOwner | 1 | 2018 | ||
| Walker Paul Edward | Director; TenPercentOwner | 3 | 2018–2024 | ||
| Eansor Norman David | Director | 9 | 2018–2025 | ||
| Vera Juan | Director; Director,Officer; Officer | Chief Development Officer; Chief Executive Officer; Chief Scientific Officer & COO; President and CEO | 11 | 2018–2025 | |
| Wilson John Robert | Director | 8 | 2018–2023 | ||
| Kim Anthony H. | Officer | Chief Financial Officer | 6 | 2018–2022 | |
| Hoang Tsvetelina P | Officer | VP, Research and Development | 5 | 2018–2023 | |
| Leen Ann M. | Officer | Chief Scientific Officer | 2 | 2018–2021 | |
| Moseley Ken | Officer | General Counsel | 1 | 2018 | |
| Koneru Mythili | Officer | Chief Medical Officer; Snr VP, Clinical Development | 5 | 2019–2023 | |
| ELMS STEVE | Director | 10 | 2019–2025 | ||
| Agopyan Nadia | Officer | SVP, Regulatory Affairs; VP, Regulatory Affairs | 6 | 2019–2023 | |
| Garrett Gerald | Officer | Vice President, Clinical Ops. | 4 | 2020–2022 | |
| Szymanska Anna | Officer | Vice President, Quality | 5 | 2020–2023 | |
| Knobil Katharine | Director | 6 | 2021–2025 | ||
| Lurier Eliot M | Officer | Interim CFO | 1 | 2023 | |
| Corzo Kathryn Penkus | Director | 2 | 2025 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2024-12-30 | Marker Therapeutics, Inc. | Biotechnology | $16,100,000 | $16,100,000 | 5 | 1 |
| 2018-05-24 | TAPIMMUNE INC. | Biotechnology | $3,100,000 | $3,100,000 | 1 | 1 |
| 2017-06-29 | TAPIMMUNE INC | Biotechnology | $6,190,002 | $6,190,002 | 87 | 1 |
| 2016-08-25 | TAPIMMUNE INC | Biotechnology | Indefinite | $0 | 11 | 1 |
| 2016-08-23 | TAPIMMUNE INC | Biotechnology | $5,000,000 | $3,135,195 | 46 | 2 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | MARKER THERAPEUTICS, INC. | State business registries | name and state | |
| Business registration | MARKER THERAPEUTICS, INC. | State business registries | name and state | |
| Federal award recipient | MARKER THERAPEUTICS INC | Federal spending (USAspending) | name and state | |
| Form D issuer | Marker Therapeutics, Inc. | Form D private offerings | CIK (EXACT) | |
| SEC filer | Marker Therapeutics, Inc. | SEC filers (EDGAR) | CIK (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.